Only 25% of multidrug-resistant tuberculosis (MDR-TB) cases are currently diagnosed. Line
probe assays (LPAs) enable rapid drug-susceptibility testing for rifampicin (RIF) and …

BACKGROUND: Drug-resistant tuberculosis (TB), especially multidrug-resistant (MDR,
resistance to rifampicin and isoniazid) disease, is associated with a worse patient outcome …

We aimed to characterize metabolites during tuberculosis (TB) disease and identify new
pathophysiologic pathways involved in infection as well as biomarkers of TB onset …

Background: Tuberculosis, including multidrug-resistant tuberculosis (MDR-TB), is a major
global health problem. Individuals with tuberculosis disease commonly exhibit vitamin D …

We report the discovery and confirmation of 23 novel mutations with previously
undocumented role in isoniazid (INH) drug resistance, in catalase-peroxidase (katG) gene of …

Rates and risk factors for acquired drug resistance and association with outcomes among
patients with multidrug-resistant tuberculosis (MDR TB) are not well defined. In an MDR TB …

SETTING: National tuberculosis (TB) treatment facility in the country of Georgia. OBJECTIVE:
To determine the prevalence of diabetes mellitus (DM) and pre-DM among patients with TB …

Background The objectives of the study were to compare the performance of line probe
assay (GenoType MTBDR plus) with solid culture method for an early diagnosis of multidrug …

Background Bedaquiline and delamanid are newly available drugs for treating multidrug-
resistant tuberculosis (MDR-TB); however, there are limited data guiding their use and no …

Background There is an urgent demand for rapid and accurate drug-susceptibility testing for
the detection of multidrug-resistant tuberculosis. The GenoType MTBDR plus assay is a …